clinical trials | Frontier Small Caps

Revive Therapeutics Provides Update of Phase 3 Clinical Study...

Revive will remain with the current protocol’s primary endpoint of proportion of patients meeting an endpoint of hospitalization or death..

Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

Rakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...

Rakovina Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor....

Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

The Company is finalizing the Phase 3 study protocol of apabetalone in PCC and plans to launch the trial in the first half of 2023..

Resverlogix will focus on the prevention and treatment of Post COVID-19 Conditions

The company’s new focus on patients with Post COVID-19 Conditions, known as long-COVID,

Resverlogix Publishes Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease..

“Apabetalone was associated not only with fewer negative cardiovascular outcomes, also relative improvements in liver fibrosis score"

Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update

The lead optimization program being conducted in collaboration with the University of British Columbia is progressing as planned...

Resverlogix Announces Type C Meeting with FDA for Phase 3 High-risk COVID-19 Outpatient Study

FDA has granted the request for a meeting to review the clinical trial protocol for its Phase 3 study in high-risk COVID-19 outpatients.

Play Video

Play Video

Play Video

Play Video